Ciprofloxacin/metronidazole versus β-lactam-based treatment of intra-abdominal infections: a meta-analysis of comparative trials

International Journal of Antimicrobial Agents

Volumn 28, Issue 3, 2006, Pages 159-165

  Matthaiou, Dimitrios K ^a   Peppas, George ^b   Bliziotis, Ioannis A ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Appendicitis; Diverticulitis; Morbidity; Mortality; Peritonitis; Quinolones; Toxicity

Indexed keywords

BETA LACTAM; CIPROFLOXACIN; METRONIDAZOLE;

ABDOMINAL INFECTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA BASE; DRUG FATALITY; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ABDOMEN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; HUMANS; METRONIDAZOLE; PUBMED; RANDOMIZED CONTROLLED TRIALS;

EID: 33747090597     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.04.005     Document Type: Short Survey

References (33)

1. McClean K.L., Sheehan G.J., and Harding G.K. Intraabdominal infection: a review. Clin Infect Dis 19 (1994) 100-116
2. Gorbach S.L., Thadepalli H., and Norsen J. Anaerobic microorganisms in intraabdominal infections. In: Balows A., DeHaan R., Dowall V., and Guze L. (Eds). Anaerobic bacteria. Role in disease (2005), Charles C. Thomas, Springfield, IL 399-407
3. Swenson R.M., Lorber B., Michaelson T.C., and Spaulding E.H. The bacteriology of intra-abdominal infections. Arch Surg 109 (1974) 398-399
4. Falagas M.E., Barefoot L., Griffith J., Ruthazar R., and Snydman D.R. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 15 (1996) 913-921
5. Bohnen J.M., Solomkin J.S., Dellinger E.P., Bjornson H.S., and Page C.P. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 127 (1992) 83-89
6. Schentag J.J., Wels P.B., Reitberg D.P., Walczak P., Van Tyle J.H., and Lascola R.J. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg 198 (1983) 35-41
7. Solomkin J.S., Fant W.K., Rivera J.O., and Alexander J.W. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 78 (1985) 85-91
8. Tyburski J.G., Wilson R.F., Warsow K.M., and McCreadie S. A trial of ciprofloxacin and metronidazole vs. gentamicin and metronidazole for penetrating abdominal trauma. Arch Surg 133 (1998) 1289-1296
9. Whiting J.L., Cheng N., and Chow A.W. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria. Antimicrob Agents Chemother 31 (1987) 1379-1382
10. Brook I. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Antimicrob Agents Chemother 37 (1993) 997-1000
11. Lettieri J.T., Rogge M.C., Kaiser L., Echols R.M., and Heller A.H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 36 (1992) 993-996
12. Thadepalli H., Bansal M.B., Rao B., et al. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev Infect Dis 10 (1988) 505-515
13. Wise R., and Donovan I.A. Tissue penetration and metabolism of ciprofloxacin. Am J Med 82 (1987) 103-107
14. Lee N., Yuen K.Y., and Kumana C.R. Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Drugs 63 (2003) 1511-1524
15. Powell L.L., and Wilson S.E. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt) 1 (2000) 57-63
16. Khan K.S., Daya S., and Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 156 (1996) 661-666
17. Moher D., Jadad A.R., and Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 12 (1996) 195-208
18. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
19. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
20. Cohn S.M., Lipsett P.A., Buchman T.G., et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232 (2000) 254-262
21. Hoogkamp-Korstanje J.A. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection 23 (1995) 278-282
22. Levine D.P., McNeil P., and Lerner S.A. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 87 5A (1989) 160S-163S
23. Solomkin J.S., Reinhart H.H., Dellinger E.P., et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223 (1996) 303-315
24. Solomkin J.S., Dellinger E.P., Bohnen J.M., and Rostein O.D. The role of oral antimicrobials for the management of intra-abdominal infections. New Horiz 6 2 Suppl. (1998) S46-S52
25. Starakis I., Karravias D., Asimakopoulos C., et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) + metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents 21 (2003) 49-57
26. Walters D.J., Solomkin J.S., and Paladino J.A. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 16 (1999) 551-561
27. Yoshioka K., Youngs D.J., and Keighley M.R. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 19 (1991) 25-29
28. Barie P.S. Serious intra-abdominal infections. Curr Opin Crit Care 7 (2001) 263-267
29. Cinat M.E., and Wilson S.E. New advances in the use of antimicrobial agents in surgery: intra-abdominal infections. J Chemother 11 (1999) 453-463
30. Gnocchi C.A. Intra-abdominal infection and new quinolones. Medicina (B Aires) 59 (1999) 47-54
31. 2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams. Pediatr Res 35 (1994) 299-302
32. Falagas M.E., McDermott L., and Snydman D.R. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group. Antimicrob Agents Chemother 41 (1997) 2047-2049
33. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37 (2003) 997-1005